Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals.

Autor: Brum WS; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil., Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; King's College London, Institute of Psychiatry, Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway., Simrén J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., di Molfetta G; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Benedet AL; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Zimmer ER; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.; Department of Pharmacology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.; Graduate Program in Biological Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.; McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, Canada., Lantero-Rodriguez J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Montoliu-Gaya L; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Jeromin A; ALZpath. Inc, Carlsbad, California, USA., Aarsand AK; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; The Norwegian Organization for Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway., Bartlett WA; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; School of Science and Engineering, University of Dundee, Dundee, UK., Calle PF; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; Department of Laboratory Medicine, La Paz University Hospital, Madrid, Spain., Coşkun A; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; School of Medicine, Department of Medical Biochemistry, Acibadem Mehmet Ali Aydınlar University, Istanbul, Turkey., Díaz-Garzón J; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; Department of Laboratory Medicine, La Paz University Hospital, Madrid, Spain., Jonker N; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; Certe, Wilhelmina Ziekenhuis Assen, Assen, the Netherlands., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Sandberg S; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; The Norwegian Organization for Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway.; Department of Global Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway., Carobene A; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Milan, Italy.; Laboratory Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Feb; Vol. 20 (2), pp. 1284-1297. Date of Electronic Publication: 2023 Nov 20.
DOI: 10.1002/alz.13518
Abstrakt: Introduction: Blood biomarkers have proven useful in Alzheimer's disease (AD) research. However, little is known about their biological variation (BV), which improves the interpretation of individual-level data.
Methods: We measured plasma amyloid beta (Aβ42, Aβ40), phosphorylated tau (p-tau181, p-tau217, p-tau231), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) in plasma samples collected weekly over 10 weeks from 20 participants aged 40 to 60 years from the European Biological Variation Study. We estimated within- (CV I ) and between-subject (CV G ) BV, analytical variation, and reference change values (RCV).
Results: Biomarkers presented considerable variability in CV I and CV G . Aβ42/Aβ40 had the lowest CV I (≈ 3%) and p-tau181 the highest (≈ 16%), while others ranged from 6% to 10%. Most RCVs ranged from 20% to 30% (decrease) and 25% to 40% (increase).
Discussion: BV estimates for AD plasma biomarkers can potentially refine their clinical and research interpretation. RCVs might be useful for detecting significant changes between serial measurements when monitoring early disease progression or interventions. Highlights Plasma amyloid beta (Aβ42/Aβ40) presents the lowest between- and within-subject biological variation, but also changes the least in Alzheimer's disease (AD) patients versus controls. Plasma phosphorylated tau variants significantly vary in their within-subject biological variation, but their substantial fold-changes in AD likely limits the impact of their variability. Plasma neurofilament light chain and glial fibrillary acidic protein demonstrate high between-subject variation, the impact of which will depend on clinical context. Reference change values can potentially be useful in monitoring early disease progression and the safety/efficacy of interventions on an individual level. Serial sampling revealed that unexpectedly high values in heathy individuals can be observed, which urges caution when interpreting AD plasma biomarkers based on a single test result.
(© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: